Program » Search the meeting program and create your personalized schedule » myISPORBaltimore
(Program subject to change)

Program Monday, May 21, 2018

7:00 AM - 6:00 PM
REGISTRATION HELP DESK HOURS (Charles Street Lobby, Baltimore Convention Center)
7:00 AM - 6:00 PM
MULTI-FAITH PRAYER ROOM (Ballroom VIP East Suite (Level 400))
7:00 AM - 6:00 PM
NURSING MOTHER'S ROOM (Ballroom VIP Suite West (Level 400))
8:00 AM - 6:00 PM
SPEAKER READY ROOM HOURS (Room 311 (Level 300))
8:30 AM - 7:45 PM
EXHIBIT/POSTER HALL HOURS (Hall B,C,D, Baltimore Convention Center)
12:30 PM - 1:30 PM
EDUCATIONAL SYMPOSIUM
12:30 PM - 1:30 PM
Room: 309 (Level 300)
21st CENTURY CURES ACT AND THE FUTURE OF REAL-WORLD EVIDENCE

(Sponsored by Syneos Health)

8:30 AM - 2:00 PM
RESEARCH POSTER PRESENTATIONS - SESSION I
8:30 AM - 10:30 AM
WELCOME & FIRST PLENARY SESSION
Room: Hall A (Level 100)
WELCOME FROM ISPOR CEO/EXECUTIVE DIRECTOR
Speaker: Nancy S. Berg
CEO/Executive Director, ISPOR - The Professional Society for Health Economics and Outcomes Research, Lawrenceville, NJ, USA
Room: Hall A (Level 100)
PRESIDENTIAL ADDRESS
Speaker: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Room: Hall A (Level 100)
MEETING PROGRAM OVERVIEW FROM PROGRAM COMMITTEE CO-CHAIRS
Speaker: C. Daniel Mullins, PhD
Professor & Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
Speaker: Rachael L. Fleurence, PhD
Executive Director, National Evaluation System for Health Technology Coordinating Center (NESTcc), Medical Device Innovation Consortium (MDIC), Arlington, VA, USA
Room: Hall A (Level 100)
2018 ISPOR AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARD
AWARDEE: F. Reed Johnson, PhD
Professor, Duke School of Medicine, Duke Clinical Research Institute, Duke University, Durham, NC, USA
Room: Hall A (Level 100)
FIRST PLENARY SESSION: INFLECTION POINT FOR REAL-WORLD EVIDENCE? THE TRANSFORMATIONAL ROLE OF DIGITAL HEALTH
In the last 10 years, we have witnessed an exponential increase in the generation of digital health data from electronic health records (EHRs), claims, billing and patient- and device-generated data. At the same time, it’s being increasingly recognized that traditional clinical trials are expensive, lengthy, and do not adequately study the patient’s specific characteristics (e.g. age, gender, ethnicity, co-morbidities) treatment preferences. The promises of real-world evidence – lower cost; higher quality (including retaining randomization); near real time; regulatory, coverage, and clinical support; and patient decision making – are being addressed on many fronts in a number of transformational and innovative programs. Experience and resources developed on the technical, governance, and policy fronts are supporting accelerated learning. Are we finally at the inflection point to deliver on the promises of real-world evidence and digital health?  The panel is composed of a number of leaders who have been working in this area on cutting-edge initiatives and will be interviewed on what they have learned to date, current barriers to the use of real-world evidence, and what the future holds both within and outside of the United States.
Moderator: Rachael L. Fleurence, PhD
Executive Director, National Evaluation System for Health Technology Coordinating Center (NESTcc), Medical Device Innovation Consortium (MDIC), Arlington, VA, USA
Speaker: Adrian F. Hernandez, MD, MHS
Vice Dean, Clinical Research, Duke University School of Medicine, Durham, NC, USA
Speaker: Michelle McMurry-Heath, MD, PhD
Worldwide Vice President and Global Head, Regulatory Affairs, Johnson & Johnson Medical Device Companies, Washington, DC, USA
Speaker: Danica Marinac-Dabic, MD, PhD, MMSc, FISPE
Director, Division of Epidemiology, Center for Devices and Radiological/OSB, U.S. Food & Drug Administration, Silver Spring, MD, USA
Speaker: Sally Okun, RN, MMHS
Vice President, Policy & Ethics, PatientsLikeMe, Cambridge, MA, USA
10:30 AM - 11:00 AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
11:00 AM - 12:00 PM
BREAKOUT SESSION

11:00 AM - 12:00 PM
Room: Hall A (Level 100)

IP1: DESIGNING A PATIENT-CENTERED VALUE FRAMEWORK TO GUIDE SHARED DECISION MAKING IN ONCOLOGY: WHY, WHAT, AND HOW?

Moderator:

Jalpa A. Doshi, PhD, Professor of Medicine, Perelman School of Medicine; Director, Economic Evaluations Unit, Center for Evidence-based Practice; Director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA

Panelists:

Henry A. Glick, PhD, Professor of Medicine, Perelman School of Medicine; Professor of Health Care Systems, Wharton School, University of Pennsylvania, Philadelphia, NY, USA

Ellen Sonet, JD, MBA, Chief Strategy and Alliance Officer, Strategy, CancerCare, New York, NY, USA

Charles E. Phelps, PhD, MBA, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Rochester, NY, USA


11:00 AM - 12:00 PM
Room: Ballroom I (Level 400)

IP2: WHAT ROLE FOR VALUE ASSESSMENT IN US PRIVATE PAYERS’ SPECIALTY DRUG COVERAGE DECISIONS?

Moderator:

James D. Chambers, PhD, MPharm, MSc, Associate Professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

Panelists:

Susan A. Cantrell, CAE, Chief Executive Officer, Academy of Managed Care Pharmacy, Alexandra, VA, USA

Sara Traigle van Geertruyden, JD, Executive Director, Partnership to Improve Patient Care, Washington, DC, USA

Randy Burkholder, BA, Vice President of Policy and Research, PhRMA, Washington, DC, USA


11:00 AM - 12:00 PM
Room: Ballroom II (Level 400)
W1: TIME TO LOOK BEYOND KAPLAN-MEIER CURVES? CHALLENGES AND OPPORTUNITIES IN OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TRIALS -- SCIENTIFIC RATIONALE FOR USING PATIENT-LEVEL BIOMEDICAL INFORMATION
Discussion Leaders:

Andrew Briggs, DPhil, William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, UK

Scott D. Ramsey, MD, PhD, Director, Public Health Sciences, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA

Yiduo Zhang, PhD, Director, Health Economics and Payer Analytics, Global Payer Evidence and Pricing, AstraZeneca, Gaithersburg, MD, USA

Pralay Mukhopadhyay, PhD, Statistician, AstraZeneca, Gaithersburg, MD, USA


11:00 AM - 12:00 PM
Room: Ballroom III (Level 400)
W2: WHAT IS PATIENT EXPERIENCE DATA? THE REGULATORY PERSPECTIVE
Discussion Leaders:

Martin Ho, MS, Associate Director for Quantitative Innovation, Center for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration, Silver Springs, MD, USA

Megan Moncur, MS, Senior Advisor, Science of Patient Input, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration, Silver Spring, MD, USA

Pujita Vaidya, MPH, Director (Acting), Decision Support and Analysis Team, Office of Strategic Programs/Office of Program and Strategic Analysis, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD, USA


11:00 AM - 12:00 PM
Room: 309 (Level 300)
W3: DIGITAL HEALTH: EVALUATING THE EVIDENCE, IDENTIFYING GAPS, PRODUCING BETTER SCIENCE
Discussion Leaders:

Penny Mohr, MA, Senior Advisor, Emerging Technology and Delivery System Innovation Research Initiatives, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, USA

Karen Schoelles, MD, SM, Director, ECRI Institute HTA Consulting Service, ECRI Institute, Plymouth Meeting, PA, USA

Murray Aitken, MBA, Executive Director, IQVIA Institute for Human Data Science, New York, NY, USA

Jasmine Bihm, DrPH, MPH, Staff Fellow, Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA


11:00 AM - 12:00 PM
Room: Ballroom IV (Level 400)
P1: COST-EFFECTIVENESS STUDIES
Moderator: Kenneth M. Shermock, PharmD, PhD
Director, Center for Medication Quality and Outcomes, The Johns Hopkins Hospital, Baltimore, MD, USA

CE1

11:00 AM - 11:15 AM

COST-EFFECTIVENESS OF THREE DIFFERENT STRATEGIES FOR THE TREATMENT OF FIRST RECURRENT CLOSTRIDIUM DIFFICILE INFECTION DIAGNOSED IN A COMMUNITY SETTING

Lam SW1, Delgado D2, Chalfin DB2
1Cleveland Clinic, Cleveland, OH, USA, 2Jefferson College of Population Health at Thomas Jefferson University, Philadelphia, PA, USA

CE2

11:15 AM - 11:30 AM

MANDATORY MENINGOCOCCAL SEROGROUP B VACCINATION FOR COLLEGE STUDENTS IS NOT COST-EFFECTIVE

Leeds IL1, Thayer WM2, Sankhla P3, Bamogo A3, Namasivayam V3
1Johns Hopkins University School of Medicine, Baltimore, MD, USA, 2Johns Hopkins School of Nursing, Baltimore, MD, USA, 3Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

CE3

11:30 AM - 11:45 AM

COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AND TAS-102 IN REFRACTORY METASTATIC COLORECTAL CANCER

Cho SK, Hay JW, Barzi A
University of Southern California, Los Angeles, CA, USA

CE4

11:45 AM - 12:00 PM

AN ECONOMIC EVALUATION OF A FAMILIAL CANCER RISK MANAGEMENT PROGRAM FOR BRCA MUTATION CARRIERS: AN AUSTRALIAN PERSPECTIVE

Petelin L1, Liew D2, Mitchell G3, James PA3, Trainer AH3
1University of Melbourne, Parkville, Australia, 2Monash University, Melbourne, Australia, 3Peter MacCallum Cancer Centre, Parkville, Australia

11:00 AM - 12:00 PM
Room: 310 (Level 300)
P2: ADDICTION AND MENTAL HEALTH STUDIES
Moderator: Eric Slade, PhD
Research Health Scientist, University of Maryland, Baltimore, MD, USA

MH1

11:00 AM - 11:15 AM

DESCRIPTIVE RESULTS FROM THE PRESCRIPTION OPIOID MISUSE AND ABUSE QUESTIONNAIRE (POMAQ) VALIDATION STUDY

Coyne KS1, Barsdorf AI2, Poon J3, Maziere JA4, Pierson RF5, Schnoll S6, Butler SF7, Farrar JT8, Porter LN9, Franks Jr MJ10
1Evidera, Bethesda, MD, USA, 2Pfizer, Inc, New York, NY, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4PPD, Wilmington, NC, USA, 5Janssen Global Services, LLC, Raritan, NJ, USA, 6Pinney Associates, Bethesda, MD, USA, 7Inflexxion, Inc., Waltham, MA, USA, 8University of Pennsylvania, Philadelphia, PA, USA, 9Health ResearchTx, Trevose, PA, USA, 10Naval Medical Center, Portsmouth, VA, USA

MH2

11:15 AM - 11:30 AM

ECONOMIC BURDEN OF OPIOID USE AMONG PREGNANT WOMEN: EVIDENCE FROM THE MEDICAL EXPENDITURE PANEL SURVEY, 2011-2015

Chen G, Xiao H
University of Florida, Gainesville, FL, USA

MH3

11:30 AM - 11:45 AM

GEOGRAPHIC VARIATION OF HIGH-RISK OPIOID USE AND RISK OF OVERDOSE AMONG DISABLED MEDICARE BENEFICIARIES IN THE US FROM 2011 TO 2015

Lo-Ciganic W1, Gellad WF2, Zhou L3, Donohue JM4, Roubal A5, Hines L6, Lindermann J7, Malone DC3, Bhattacharjee S3, Lee JK3, Kwoh CK3
1The University of Arizona, Tucson, AZ, USA, 2Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, 3University of Arizona, Tucson, AZ, USA, 4University of Pittsburgh, Pittsburgh, PA, USA, 5Robert Wood Johnson Foundation, Princeton, NJ, USA, 6Pharmacy Quality Alliance, Springfield, VA, USA, 7ESRI Inc., Broomfield, CO, USA

MH4

11:45 AM - 12:00 PM

EXAMINING PARKINSON’S DISEASE PSYCHOSIS TREATMENT OUTCOMES IN THE REAL WORLD: THE INSYTE OBSERVATIONAL STUDY

Goldman J1, Fredericks D2, Trotter J3, Heywood C3, Ryan A3, Block S3, Rattana S3, Shim A2, Larsen N2
1Rush University Medical Center, Chicago, IL, USA, 2ACADIA Pharmaceuticals Inc., San Diego, CA, USA, 3Continuum Clinical, Northbrook, IL, USA
11:00 AM - 12:00 PM
ISPOR NEW PROFESSIONAL EVENT
Room: 316-317 (Level 300)
The New Professional Event, Career Advice Across The Globe: Effectively Communicating & Presenting Your Research, provides both New Professional and soon-to-graduate Student members with the opportunity to hear first-hand experiences from established ISPOR members around the world on various career related topics.
12:00 PM - 2:15 PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
12:30 PM - 1:30 PM
ISPOR STUDENT RESEARCH SHOWCASE
Room: 310 (Level 300)
The Student Research Showcase will feature three outcomes research studies, conducted by ISPOR student members and presented during the conference. A brief summary of the research study, the methods, challenges, the so what, and conclusions will be presented by each student author followed by a discussion of relevance of their research to the conference theme of Real-World Evidence, Digital Health, and the New Landscape for Health Decision Making. There will be time for Q&A from the moderators and the audience at the end of each presentation.
Moderator: Zeba M. Khan, MS, RPh, PhD
ISPOR Student Network Advisor and Vice President, Celgene Corporation, Summit, NJ, USA
Moderator: Laura Pizzi, MPH, RPh, PharmD
Professor and Director, Center for Health Outcomes, Policy & Economics, Rutgers University, Ernest Mario School of Pharmacy, New Brunswick, NJ, USA
Speaker: Judith John, PharmD
Pharm D Intern, National College of Pharmacy, KMCT Medical college, Manassery, Kerala, India
Speaker: Youngran Kim, MPH
Doctoral Student, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA
Speaker: Wan-Ting Hsu, MS
School of Public Health, Harvard University, Boston, MA, USA
12:30 PM - 2:00 PM
ISPOR WOMEN IN HEALTH ECONOMICS AND OUTCOMES RESEARCH
Room: 307 (Level 300)
The vision of ISPOR’s new “Women in HEOR” initiative is to support the growth, development, and contribution of women in health economics and outcomes research (HEOR); to serve as a catalyst for women’s leadership in the field, and to offer a platform for ISPOR women to collaborate, network, share, and mentor each other. This session will outline the initiative’s work to date and feature a special guest speaker, Laurie Cooke, CEO of the Healthcare Businesswomen’s Association. The session will be led by ISPOR President (2017-2018) Shelby D. Reed, PhD, Duke University, Durham, NC, USA and Olivia Wu, PhD, University of Glasgow, Glasgow, UK.
1:00 PM - 2:00 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION I
2:15 PM - 3:15 PM
SPECIAL SESSION
3:15 PM - 3:45 PM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II
3:30 PM - 7:30 PM
RESEARCH POSTER PRESENTATIONS - SESSION II
3:45 PM - 4:45 PM
BREAKOUT SESSION

3:45 PM - 4:45 PM
Room: Ballroom II (Level 400)

IP3: THE MACHINE LEARNING DEBATE: PANACEA OR THE NEW ALCHEMY?

Moderator:

Sreeram Ramagopalan, Ph.D, Director, Center for Observational Research and Data Sciences (CORDS), Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK

Panelists:

Andrew Briggs, DPhil, William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK

Gorana Capkun-Niggli, PhD, Head of HEOR Innovation, Novartis Pharma AG, Basel, Switzerland

Radek Wasiak, Ph.D, Vice President, General Manager, Real-World Evidence, Evidera, London, UK


3:45 PM - 4:45 PM
Room: Hall A (Level 100)

IP4: INCORPORATING QUANTITATIVE PATIENT PREFERENCE INFORMATION INTO HEALTHCARE DECISION-MAKING PROCESSES: IS HEALTH TECHNOLOGY ASSESSMENT FALLING BEHIND?

Moderator:

Paula Lorgelly, BSc(Hons), PhD, PGCAP, Deputy Director, Office of Health Economics, London, UK

Panelists:

David J. Mott, MSc, Economist, Office of Health Economics, London, UK

A. Brett Hauber, PhD, Senior Economist & Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA

Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research, Professor, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada


3:45 PM - 4:45 PM
Room: Ballroom I (Level 400)
W4: BIOSIMILARS, UTILIZATION, AND POST-MARKETING SURVEILLANCE IN THE UNITED STATES (INVITED WORKSHOP)
Discussion Leaders:

Cate Lockhart, PharmD, PhD, Program Director, Biologics and Biosimilars Collective Intelligence Consortium, Alexandria, VA, USA

Mark J. Cziraky, PharmD, CLS, Vice President of Research, Healthcore, Wilmington, DE, USA

Mike Blum, MD, MPH, Deputy Director, Office of Pharmacovigilance and Epidemiology, U.S. Food & Drug Administration, Silver Spring, MD, USA


3:45 PM - 4:45 PM
Room: Ballroom III (Level 400)
W5: ADJUSTING FOR BETWEEN-TRIAL DIFFERENCES IN THE SCHEDULE OF ASSESSMENT FOR DISEASE PROGRESSION IN IMMUNO-ONCOLOGY AND ITS IMPACT ON INDIRECT TREATMENT COMPARISONS
Discussion Leaders:

Venediktos Kapetanakis, PhD, Lead Statistician, Evidera, London, UK

Michael Schlichting, Director, Global Biostatistics and Epidemiology, Merck KGaA, Darmstadt, Germany

John William Stevens, PhD, Director, HEDS, ScHARR, Reader in Decision Science, University of Sheffield, Sheffield, UK


3:45 PM - 4:45 PM
Room: Ballroom IV (Level 400)
W6: ECONOMIC EVALUATION OF VACCINATION PROGRAMS: EXPLORING MULTIPLE METHODS
Discussion Leaders:

Josephine Mauskopf, PhD, MHA, Vice President, Health Economics, RTI Health Solutions, Durham, NC, USA

David E Bloom, PhD, Clarence James Gamble Professor of Economics and Demography, TH Chan School of Public Health, Harvard University, Boston, MA, USA

Americo Cicchetti, PhD, Professor/Director, Graduate School of Health Economics and Management, Università Cattolica del Sacro Cuore, Rome, Italy


3:45 PM - 4:45 PM
Room: 309 (Level 300)
P3: MEDICAL DEVICE AND DIAGNOSTICS STUDIES
Moderator: Jan Pietzsch, PhD
President & Chief Executive Officer, Wing Tech Inc., Irvine, CA, USA

MD1

3:45 PM - 4:00 PM

A REAL-WORLD ASSESSMENT OF THE CLINICAL AND ECONOMIC IMPACT OF POWERED VS MANUAL ENDOSCOPIC STAPLERS WHEN USED IN CONJUNCTION WITH BUTTRESS IN BARIATRIC SURGERY

Lim S1, Roy S1, Yadalam S2, Johnston SS3
1Ethicon Inc, Somerville, NJ, USA, 2Johnson & Johnson Co., New Brunswick, NJ, USA, 3Johnson & Johnson, Inc., New Brunswick, NJ, USA

MD2

4:00 PM - 4:15 PM

A COMPARISON OF LONG-TERM PATIENT OUTCOMES AFTER HEART VALVE REPLACEMENT WITH BIOLOGICAL OR MECHANICAL VALVES IN MEDICARE BENEFICIARIES

Du D1, Lu X1, McKean S2, Warnock R2, Laschinger J1, Loyo-Berríos N1, Marinac-Dabic D1
1U.S. Food and Drug Administration, Silver Spring, MD, USA, 2Acumen LLC, Burlingame, CA, USA

MD3

4:15 PM - 4:30 PM

LINKAGE BETWEEN ORTHOPEDIC REGISTRY AND ADMINISTRATIVE DATA USING INDIRECT IDENTIFIERS FOR NATIONAL DEVICE INFRASTRUCTURE DEVELOPMENT

Mao J1, Etkin C2, Lewallen DG3, Sedrakyan A4
1Weill Cornell Medical College, New York, NY, USA, 2American Joint Replacement Registry, Rosemont, IL, USA, 3Mayo Clinic, Rochester, MN, USA, 4Weill Cornell Medicine, New York, NY, USA

MD4

4:30 PM - 4:45 PM

PAYER COVERAGE AND EVIDENCE REQUIREMENTS FOR ONCOLOGY LIQUID BIOPSY TESTING IN THE UNITED STATES: CURRENT STATE AND FILLING THE GAPS

Spinner DS1, Faulkner EC2, Ringo MC2, Mihos MC1, Joines J3
1Evidera, Chapel Hill, NC, USA, 2Evidera, Raleigh, NC, USA, 3PPD, Raleigh, NC, USA

3:45 PM - 4:45 PM
Room: 310 (Level 300)
P4: BENEFITS, VALUE, AND COVERAGE STUDIES
Moderator: Ya-Chen Tina Shih, PhD
Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

VA1

3:45 PM - 4:00 PM

DOES THE TIMING OF A DRUG’S COSTS AND BENEFITS INFLUENCE US PAYER COVERAGE OF SPECIAL DRUGS?

Kim DD, Chambers J, Pope E, Cohen JT, Neumann PJ
Tufts Medical Center, Boston, MA, USA

VA2

4:00 PM - 4:15 PM

TRENDS IN THE ECONOMIC VALUE OF NEWLY APPROVED CANCER THERAPIES IN THE U.S.

Chen AJ1, Hu X1, Jena AB2, Goldman DP1
1University of Southern California, Los Angeles, CA, USA, 2Harvard Medical School, Boston, MA, USA

VA3

4:15 PM - 4:30 PM

“IT’S TOUGH TO MAKE PREDICTIONS, ESPECIALLY ABOUT THE FUTURE”: COMPARING LIFE EXPECTANCY PREDICTIONS BASED ON PERIOD VERSUS COHORT LIFE TABLES

Garrison LP, Li M
University of Washington, Seattle, WA, USA

VA4

4:30 PM - 4:45 PM

ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT INVESTMENT FROM THE NHS PERSPECTIVE

Mennini FS1, Marcellusi A1, Viti R1, Kondili L2, Rosato S2, Vella S2, on behalf of PITER collaboration study group .2
1Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, 2Center for Global Health, Istituto Superiore di Sanità, Rome, Italy
5:00 PM - 6:00 PM
BREAKOUT SESSION

5:00 PM - 6:00 PM
Room: Ballroom II (Level 400)

IP5: SHOULD WE MOVE BEYOND CONVENTIONAL COST-EFFECTIVENESS ANALYSIS? IF SO, HOW?

Moderator:

Darius N. Lakdawalla, PhD, Quintiles Chair, Pharmaceutical Development and Regulatory Innovation, University of Southern California, Los Angeles, CA, USA

Panelists:

Peter J. Neumann, ScD, Professor & Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA bio

Charles E. Phelps, PhD, MBA, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Rochester, NY, USA

Jeroen P Jansen, PhD, Lead Scientific Advisor - Open Source Value Project, Innovation and Value Initiative; Precision Health Economics, Los Angeles, CA, USA


5:00 PM - 6:00 PM
Room: Ballroom I (Level 400)

IP6: INCREASING MEDICAL DEVICE EVIDENCE FOR PAYERS, PROVIDERS, AND HTA BODIES: WHO’S RESPONSIBLE FOR GENERATING THE EVIDENCE?

Moderator:

Karen Worley, PhD, Research Manager, Comprehensive Health Insights, Humana, Cincinnati, OH, USA

Panelists:

Bruce Gingles, BA, Vice President, Global Technology Assessment and Healthcare Policy, Cook Medical, Bloomington, IN, USA

Suzanne Belinson, PhD, Executive Director, Blue Cross and Blue Shield Association, Chicago, IL, USA

Harindra C Wijeysundera, MD, PhD, Vice President, Medical Devices and Clinical Interventions, CADTH, Ottawa, ON, Canada


5:00 PM - 6:00 PM
Room: Hall A (Level 100)

IP7: THE CHANGING LANDSCAPE OF HEALTHCARE DECISION MAKING: HOW CAN WE LEVERAGE THE USE OF REAL-WORLD EVIDENCE FOR REGULATORY, COVERAGE, AND CLINICAL DECISION MAKING?

Moderator:

Rachael Fleurence, PhD, Executive Director, National Evaluation System for Health Technology Coordinating Center (NESTcc), Medical Device Innovation Consortium (MDIC), Arlington, VA, USA

Panelists:

Owen Faris, PhD, Clinical Trials Director, Office of Device Evaluation, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA

Kathleen Blake, MD, MPH, Vice President, Healthcare Quality, American Medical Association (AMA), Washington, DC, USA

Naomi Aronson, PhD, Executive Director of Clinical Evaluation, Innovation, and Policy, Blue Cross and Blue Shield Association, Chicago, IL, USA


5:00 PM - 6:00 PM
Room: Ballroom III (Level 400)
W7: ARTIFICIAL INTELLIGENCE AND PRECISION MEDICINE: DOES THE HEALTH ECONOMIST NEED TO ADAPT TO THE MACHINE?
Discussion Leaders:

Augustin Terlinden, MSc, Actuary and Health Economist, Independent Researcher, Brussels, Belgium

Patricia A Deverka, MD, MS, MBE, Senior Researcher, American Institutes for Research, Chapel Hill, NC, USA

Amine Aissaoui, PharmD, MSc, Researcher, LEDA-LEGOS, Paris Dauphine University, PSL, Paris, France

Olivier Ethgen, MSc, PhD, Scientific Director, SERFAN innovation, Namur, Belgium


5:00 PM - 6:00 PM
Room: Ballroom IV (Level 400)
W8: ASSESSING PATIENT FUNCTIONING IN DRUG DEVELOPMENT USING PERFORMANCE OUTCOME ASSESSMENTS: EVIDENTIARY, METHODOLOGICAL, AND OPERATIONAL CONSIDERATIONS
Discussion Leaders:

Elektra Papadopoulos, MD, MPH, Associate Director, Clinical Outcome Assessments Staff, Office of New Drugs, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD, USA

Heather Adams, PhD, Associate Professor, Department of Neurology & Pediatrics, University of Rochester Medical Center, Rochester, NY, USA

Daniel S. Rooks, PhD, Director, Musculoskeletal Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA, USA

Daniel C. Chung, DO, MA, Clinical Ophthalmic Lead, Spark Therapeutics, Philadelphia, PA, USA


5:00 PM - 6:00 PM
Room: 309 (Level 300)
P5: COST STUDIES
Moderator: C. Edward Chou, PhD
Associate Professor, Auburn University, Auburn, AL, USA

CS1

5:00 PM - 5:15 PM

WITHDRAWN

CS2

5:15 PM - 5:30 PM

CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN OF OSTEOARTHRITIS (OA) AMONG NONINSTITUTIONALIZED ADULTS IN THE UNITED STATES (US)

Zhao X1, Shah D1, Gandhi K2, Wei W3, Dwibedi N1, Webster L4, Sambamoorthi U5
1West Virginia University, School of Pharmacy, Morgantown, WV, USA, 2Teva Pharmaceutical Industries, Frazer, PA, USA, 3Regeneron Pharmaceuticals, Tarrytown, NY, USA, 4PRA Health Sciences, Salt Lake City, UT, USA, 5West Virginia University, Morgantown, WV, USA

CS3

5:30 PM - 5:45 PM

PROJECTED MEDICARE SAVINGS ASSOCIATED WITH LOWERING THE RISK OF TOTAL HIP ARTHROPLASTY REVISION: AN ADMINISTRATIVE CLAIMS DATABASE ANALYSIS

Ackerman SJ1, Knight T2, Wahl PM2
1Covance Market Access Services Inc., San Diego, CA, USA, 2Covance Market Access Services Inc., Gaithersburg, MD, USA

CS4

5:45 PM - 6:00 PM

ALZHEIMER’S ATTRIBUTABLE COSTS IN THE UNITED STATES: A SECONDARY ANALYSIS OF MEDICAL EXPENDITURE PANEL SURVEY 2011-2015

Shuvo TA, Haider MR, Khan MM
University of South Carolina, Columbia, SC, USA

5:00 PM - 6:00 PM
Room: 310 (Level 300)
P6: ANALYTIC AND MODELING METHODS
Moderator: Michael Eaddy, PharmD, PhD
Vice President, Xcenda, Palm Harbor, FL, USA

MO1

5:00 PM - 5:15 PM

UNITED STATES VALUATION OF EQ-5D-5L HEALTH STATES: AN INITIAL MODEL USING A STANDARDIZED PROTOCOL

Pickard AS1, Law EH1, Jiang R1, Oppe M2, Shaw JW3, Xie F4, Boye KS5, Gong CL6, Chapman RH7, Balch A8
1University of Illinois at Chicago, Chicago, IL, USA, 2EuroQol Research Foundation, Rotterdam, The Netherlands, 3Bristol-Myers Squibb, Lawrenceville, NJ, USA, 4McMaster University, Hamilton, ON, Canada, 5Eli Lilly and Company, Indianapolis, IN, USA, 6University of Southern California, Los Angeles, CA, USA, 7Institute for Clinical and Economic Review, Boston, MA, USA, 8Patient Advocate Foundation, Hampton, VA, USA

MO2

5:15 PM - 5:30 PM

A PREDICTION MODEL FOR LENGTH OF STAY IN THE ICU AMONG SEPTIC PATIENTS: A MACHINE LEARNING APPROACH

Ling Y1, Chen Y2, Chirikov V1, Xie J3, Qiu H3, Otgonsuren Z1, Dong P2, Gao X1
1Pharmerit International, Bethesda, MD, USA, 2Pfizer Investment Co., Ltd., Beijing, China, 3Zhongda Hospital, Nanjing, China

MO3

5:30 PM - 5:45 PM

IDENTIFYING AND ASSESSING THE FEASIBILITY OF PROPOSED ALTERNATIVE APPROACHES TO QALY ESTIMATION WITHIN COST-EFFECTIVENESS MODELS USING A SYSTEMATIC LITERATURE REVIEW

Brouwer E, Carlson JJ
University of Washington, Seattle, WA, USA

MO4

5:45 PM - 6:00 PM

GLOBALIZATION MODULE FOR A DIABETES PROGRESSION PREDICTION MODEL: THE BUILDING, RELATING, ACTING, AND VALIDATING OUTCOMES (BRAVO) MODEL

Shao H1, Yang S2, Fonseca V3, Shi L1
1Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA, 2Louisiana State University Health Science Center, New Orleans, LA, USA, 3Tulane University School of Medicine, New Orleans, LA, USA
6:00 PM - 7:45 PM
EXHIBITORS' OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II
6:00 PM - 7:00 PM
MEET THE WOMEN IN HEOR SPEAKERS RECEPTION
Join us for the ISPOR Women in Health Economics and Outcomes Research (HEOR) reception at the ISPOR booth (#213) in the exhibit hall. Meet the speakers from the Women in HEOR open meeting held earlier in the day and network with others who support the advancement of women in healthcare.
6:15 PM - 7:15 PM
BREAKOUT SESSION

6:15 PM - 7:15 PM
Room: Ballroom I (Level 400)
F1: HEALTH STATE UTILITY (HSU) GOOD PRACTICES TASK FORCE RECOMMENDATIONS FOR IDENTIFICATION AND USE OF HSU DATA IN COST-EFFECTIVENESS IN DECISION MODELLING
Moderator:

John E. Brazier, PhD, MSc, Dean, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Speakers:

Andrew Lloyd, PhD, Director, Acaster Lloyd Consulting Ltd., London, UK

Bruce Crawford, MPH, MA, Vice President, Real World Evidence, APAC, Syneos Health, Tokyo, Japan

A. Simon Pickard, PhD, Professor, Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL, USA


6:15 PM - 7:15 PM
Room: Ballroom II (Level 400)
F2: HANDLING MISSING VALUES IN REAL-WORLD DATA: ARE THERE CHALLENGES FOR REGULATORY DECISIONS FOR MEDICAL PRODUCTS?
Moderator:

Laurence Djatche, PharmD, Health Economics and Outcomes Research Post-Doctoral Fellow, College of Population Health, Thomas Jefferson University, Philadelphia, PA, USA

Speakers:

Nneka C. Onwudiwe, PhD, PharmD, MBA, PRO/PE Scientific Reviewer, Government, Silver Spring, MD, USA

Helene Karcher, PhD, Managing Vice-President and Global Head of Modeling, Analytica Laser, Basel, Switzerland

Judith J. Stephenson, SB, SM, Principal Scientist, Survey Research, HealthCore, Inc., Wilmington, DE, USA

Samuel Wilson, PhD, BS, MS, Associate Director-Statistics, Astellas Pharmaceuticals US, Inc., Northbrook, IL, USA


6:15 PM - 7:15 PM
Room: Ballroom III (Level 400)
F3: DEFINING PATIENT CENTEREDNESS AND ENGAGEMENT IN HEOR: PROPOSED DEFINITION AND STAKEHOLDER RESPONSE
Moderator:

Rachel L. Harrington, BA, Pre-Doctoral Fellow, Institute for Health Research and Policy/College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA

Speakers:

Eleanor M. Perfetto, PhD, RPh, MS, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC, USA and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland School of Pharmacy, Baltimore, MD, USA

Suzanne Schrandt, JD, Director, Patient Engagement, Arthritis Foundation, Atlanta, GA, USA

Sarah Donelson, MA, Lead, Patient-Centered Research, Genentech, San Francisco, CA, USA


6:15 PM - 7:15 PM
Room: 309 (Level 300)
F4: THE ISPOR HEOR COMPETENCIES FRAMEWORK™: GUIDING PROFESSIONAL DEVELOPMENT FOR THE FIELD OF HEOR
Moderator:

Bill Marder, PhD, MA, BA, Chief Data Strategist, IBM Watson Health, Cambridge, MA, USA

Speakers:

James F. Murray, PhD, Research Fellow, Global Health Outcomes - COE, Eli Lilly and Company, Carmel, IN, USA

Laura T. Pizzi, PharmD, MPH, Professor and Director, Center for Health Outcomes Policy and Economics, Rutgers University, Piscataway, NJ, USA


6:15 PM - 7:15 PM
Room: 310 (Level 300)
F5: ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK
Moderator:

Boxiong Tang, MD, PhD, Senior Director, Global Health Economics and Outcomes Research (GHEOR), Teva Pharmaceutical, Frazer, PA, USA

Speakers:

Jianwei Xuan, PhD, Professor and Director, Health Economic Research Institute, Sun Yat-sen University, Guangzhou, China

Larry Liu, PhD, MD, Executive Director, Merck, Rahway, NJ, USA

Makoto Kobayashi, PhD, Director and Chief Operating Officer, CRECON Medical Assessment Inc., Tokyo, Japan

Sang-Soo Lee, PhD MBA, Director, Corporate Affairs, Medtronic Korea, Seoul, Korea, Republic of (South)

6:30 PM - 7:30 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION II
7:30 PM - 9:00 PM
ISPOR GLOBAL NETWORKS RECEPTION

ISPOR invites you to a unique networking opportunity – an ISPOR Global Networks Reception! Meet with members of ISPOR Consortia in Asia, Latin America and Central and Eastern Europe, as well as ISPOR Networks in the Middle East and Africa, to exchange knowledge, share experiences, and learn about ISPOR global groups during this joint event. This reception is open to all meeting attendees interested in our Global Networks.  Join us for this truly multicultural experience and connect with regional experts in health economics, learn how members of the ISPOR Global Networks benefit from and contribute to ISPOR, and find out how you can also get involved!  

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.